Publications
Find coverage of the latest original articles on scleroderma, focusing on those with data on therapeutic interventions and those that have clinical impact.
Sponsored by Boehringer Ingelheim.
December 2025
A composite endpoint for systemic sclerosis–associated interstitial lung disease: association with mortality in two clinical trial cohorts
Respir Res. 2025;26(1):337 DOI : 10.1186/s12931-025-03401-8
Volkmann et al. validated a composite endpoint for systemic sclerosis–associated interstitial lung disease (SSc-ILD) using data from SLS II and compared performance with the SLS I cohort. The composite endpoint showed generalisability and demonstrated greater sensitivity for detecting treatment effects than forced vital capacity (FVC) alone.
Keywords:
October 2025
Nailfold capillaroscopy in patients with systemic sclerosis-associated interstitial lung disease: A substudy of the SENSCIS trial
RMD Open 2025;11:e005704 Doi:10.1136/rmdopen-2025-005704
In a substudy of the SENSCIS trial, Smith et al. showed that numerical differences in changes in capillary density assessed by nailfold capillaroscopy (NC) over 52 weeks may suggest a potential effect of nintedanib in patients at risk of ILD progression. Authors assessed microvascular changes in nailfold capillaries in patients with SSc-ILD who received nintedanib or PBO in a sub-study of the SENSCIS trial.